Pharmacovigilance Strategies Workshop

Engage in the sharing of good practices between industry representatives and seek advice from regulators in this unique workshop

Back to Agenda

Session 6: Public and Patient Involvement in Pharmacovigilance

Session Chair(s)

Wendy Huisman, PharmD

VP Quality and Patient Safety, Avanzanite Bioscience, Netherlands

Bianca Mulder, PharmD, MPharm, MSc

Pharmacovigilance Assessor, Medicines Evaluation Board, Netherlands

Patient involvement is increasing in more areas of pharmacovigilance. What influence can patient representatives have on decision making? What is the influence of the public by for example social and regular media? How did public involvement influence the communication on the Covid vaccines. Can we ethically “use” influencers/social media as pharmaceutical industry?

Speaker(s)

Ihsene Salaa-Lebcira, PhD, MPharm

Head of Safety Unit in France, Pfizer, France

Social Media on the Communication of Pfizer on COVID Vaccines

Virginie Hivert, PharmD, PhD

Therapeutic Development Director, Eurordis-Rare Diseases Europe, France

Patient Perspective

Have an account?